TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA
Brief Summary: Trial Design Patients with borderline PAH indicated by borderline mPAP values will be included in this single centre study. This clinical investigation is performed as a Proof-of-Concept (PoC) investigator initiated trial (IIT) using a prospective, randomized, double-blind, parallel group, placebo-controlled, phase IIA clinical study design. On their first visit their medical history will be obtained and physical examination will be conducted. Moreover, an electrocardiogram (ECG), laboratory testing (NT-proBNP, uric acid and other laboratory tests), echocardiography at rest and right heart catheterization will be carried out. If patients have been identified within the last 6 months before screening investigations by right heart catheterization, the measurements are considered valid as baseline investigations and will not be repeated. If patients fulfill the inclusion criteria and still suffer from borderline mPAP values they will be invited to join the study. The clinical investigations will begin within 28 days. The prospective study will comprise a 6 months study period (180 ±2 weeks) plus the screening phase up to 28 days and a follow-up phase of 30 ±7 days.


Options:
A: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: ambrisentan | Intervention Type: DRUG; Name: ambrisentan; Assigned to Arm(s): Ambrisentan
B: Arm Label: Ambrisentan; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bosentan for 16 weeks; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bosentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Bosentan for 16 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ambrisentan Verum; Type: EXPERIMENTAL; Interventions: Drug: Ambrisentan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ambrisentan; Assigned to Arm(s): Ambrisentan Verum | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Importance of Surgical Approach for Hysterectomies on Metabolic Effects Regarding Development of Insulin Resistance and Subsequent Recovery. A Randomized Controlled Study.
Brief Summary: Insulin resistance is a key reaction to surgery and trauma and reflects the degree of metabolic stress. With greater degree of insulin resistance the development of complications increase, in particular infectious complications. The aim of this study is to determine if robotic assisted total laparoscopic hysterectomy induces less insulin resistance compared to abdominal hysterectomy. Insulin resistance is measured by the hyperinsulinemic normoglycemic clamp method. In addition inflammatory factors and clinical recovery will be measured.


Options:
A: Arm Label: Robot-assisted; Type: EXPERIMENTAL; Interventions: Procedure: Hysterectomy | Arm Label: Laparoscopic Hysterectomy; Type: EXPERIMENTAL; Interventions: Procedure: Hysterectomy | Intervention Type: PROCEDURE; Name: Hysterectomy; Assigned to Arm(s): Laparoscopic Hysterectomy, Robot-assisted
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Laparoscopic Hysterectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot-assisted (Da Vinci®) laparoscopic hysterectomy | Intervention Type: PROCEDURE; Name: Conventional Laparoscopic Hysterectomy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Robot-assisted (Da Vinci®) laparoscopic hysterectomy; Assigned to Arm(s): 2
C: Arm Label: VH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vaginal hysterectomy | Arm Label: LAVH; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic assisted vaginal hysterectomy | Intervention Type: PROCEDURE; Name: Vaginal hysterectomy; Assigned to Arm(s): VH | Intervention Type: PROCEDURE; Name: Laparoscopic assisted vaginal hysterectomy; Assigned to Arm(s): LAVH
D: Arm Label: Robot assisted laparoscopic hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot assisted laparoscopic hysterectomy | Arm Label: Abdominal hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal hysterectomy; Assigned to Arm(s): Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Robot assisted laparoscopic hysterectomy; Assigned to Arm(s): Robot assisted laparoscopic hysterectomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Importance of Surgical Approach for Hysterectomies on Metabolic Effects Regarding Development of Insulin Resistance and Subsequent Recovery. A Randomized Controlled Study.
Brief Summary: Insulin resistance is a key reaction to surgery and trauma and reflects the degree of metabolic stress. With greater degree of insulin resistance the development of complications increase, in particular infectious complications. The aim of this study is to determine if robotic assisted total laparoscopic hysterectomy induces less insulin resistance compared to abdominal hysterectomy. Insulin resistance is measured by the hyperinsulinemic normoglycemic clamp method. In addition inflammatory factors and clinical recovery will be measured.


Options:
A: Arm Label: Transperitoneal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transperitoneal laparoscopic aortic lymphadenectomy | Arm Label: Extraperitoneal; Type: EXPERIMENTAL; Interventions: Procedure: Extraperitoneal laparoscopic aortic lymphadenectomy | Intervention Type: PROCEDURE; Name: Transperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Transperitoneal | Intervention Type: PROCEDURE; Name: Extraperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Extraperitoneal
B: Arm Label: Robot assisted laparoscopic hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Robot assisted laparoscopic hysterectomy | Arm Label: Abdominal hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal hysterectomy; Assigned to Arm(s): Abdominal hysterectomy | Intervention Type: PROCEDURE; Name: Robot assisted laparoscopic hysterectomy; Assigned to Arm(s): Robot assisted laparoscopic hysterectomy
C: Arm Label: Laparoscopic Radical Hysterectomy; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy | Arm Label: Abdominal radical hysterectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal radical hysterectomy | Intervention Type: PROCEDURE; Name: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy; Assigned to Arm(s): Laparoscopic Radical Hysterectomy | Intervention Type: PROCEDURE; Name: Abdominal radical hysterectomy; Assigned to Arm(s): Abdominal radical hysterectomy
D: Arm Label: Robotic surgery; Type: EXPERIMENTAL; Interventions: Procedure: Robotic surgery | Arm Label: Abdominal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal surgery | Intervention Type: PROCEDURE; Name: Robotic surgery; Assigned to Arm(s): Robotic surgery | Intervention Type: PROCEDURE; Name: Abdominal surgery; Assigned to Arm(s): Abdominal surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Enhance Motor Acute Recovery With Intensive Training After Stroke
Brief Summary: Stroke often results in limitation of arm movements, from which many people do not fully recover. We believe that early and intensive therapy is important to enhance recovery of arm movements after stroke. We are doing this research study to see how much arm movements improve with intensive therapy in patients have had a stroke in the past 6 weeks.


Options:
A: Arm Label: Core stability exercises; Type: EXPERIMENTAL; Interventions: Other: Core stability exercises (CSE), Other: Conventional Physiotherapy | Arm Label: Conventional physiotherapy (CP); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Physiotherapy | Intervention Type: OTHER; Name: Core stability exercises (CSE); Assigned to Arm(s): Core stability exercises | Intervention Type: OTHER; Name: Conventional Physiotherapy; Assigned to Arm(s): Conventional physiotherapy (CP), Core stability exercises
B: Arm Label: Device-assisted therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Device-assisted therapy | Arm Label: Therapy-based occupational therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Therapy-based occupational therapy | Intervention Type: BEHAVIORAL; Name: Device-assisted therapy; Assigned to Arm(s): Device-assisted therapy | Intervention Type: BEHAVIORAL; Name: Therapy-based occupational therapy; Assigned to Arm(s): Therapy-based occupational therapy
C: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: FAST protocol; Type: EXPERIMENTAL; Interventions: Behavioral: FAST protocol | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: FAST protocol; Assigned to Arm(s): FAST protocol
D: Arm Label: CIMT + active anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: active anodal transcranial Direct Current Stimulation (tDCS), Behavioral: Constraint Induced Movement Therapy (CIMT) | Arm Label: CIMT + sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: sham transcranial Direct Current Stimulation, Behavioral: Constraint Induced Movement Therapy (CIMT) | Arm Label: Healthy control subjects; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: active anodal transcranial Direct Current Stimulation (tDCS); Assigned to Arm(s): CIMT + active anodal tDCS | Intervention Type: DEVICE; Name: sham transcranial Direct Current Stimulation; Assigned to Arm(s): CIMT + sham tDCS | Intervention Type: BEHAVIORAL; Name: Constraint Induced Movement Therapy (CIMT); Assigned to Arm(s): CIMT + active anodal tDCS, CIMT + sham tDCS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy
Brief Summary: The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA). The secondary objective is to examine the safety and tolerability of nusinersen administered intrathecally to participants with later-onset SMA.


Options:
A: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
B: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
C: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Identification and Description of Severe Asthma Patients in a Cross-sectional Study-the IDEAL Study
Brief Summary: This will be a non-drug interventional cross-sectional study, where the screening visit and study visit can occur on the same day. Investigational product will not be administered. Approximately 790 subjects with severe asthma will be screened to achieve a total of at least 750 evaluable study subjects. The study will not include a run-in or follow-up period. This study will provide a more reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab. This study aims to estimate the potential overlap of patients eligible for treatment with mepolizumab and those eligible for treatment with omalizumab and/or reslizumab. Additionally, the current study will also ascertain and describe reslizumab eligibility with respect to both mepolizumab and omalizumab, in the severe asthma patient population.


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab
C: Arm Label: Non-drug interventional group; Type: OTHER; Interventions: Drug: Short Acting Beta Agonist (SABA) | Intervention Type: DRUG; Name: Short Acting Beta Agonist (SABA); Assigned to Arm(s): Non-drug interventional group
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tezepelumab 700 mg; Type: EXPERIMENTAL; Interventions: Biological: Tezepelumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tezepelumab; Assigned to Arm(s): Tezepelumab 700 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preschoolers Activity Trial - a Pilot Randomized Controlled to Increase Physical Activity and Reduce Sedentary Behaviour
Brief Summary: The purpose of this pilot study is to test the efficacy of the physical activity (PA) intervention protocol to increase preschoolers overall PA levels and time spent in moderate to vigorous PA (MVPA) at the day care setting. The PA intervention includes the Healthy Opportunities for Preschoolers manual, a compilation of locomotor, gross motor and movement based activities developed for preschoolers and successfully piloted for feasibility in 3 to 5 year old preschoolers by Drs. Viviene Temple, Justen O'Connor, and Patti-Jean Naylor. As well, the PA intervention includes educational workshops for the day care providers, ongoing biweekly facilitation and troubleshooting sessions with a Master Trainer, and the equipment necessary to implement the program. The study is also evaluating the efficacy of the PA intervention to decrease the amount of time spent in sedentary behaviour at the day care setting.

Secondary objectives include evaluating the effects of the PA intervention on preschool children's anthropometrics, and fundamental and gross motor skills. In addition, the intervention is also assessing the effects of the program on day care provider's attitudes, control beliefs, and self-efficacy toward incorporating PA into the day care curriculum.


Options:
A: Arm Label: Physical Activity Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Intervention; Assigned to Arm(s): Physical Activity Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bottle Weaning Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bottle Weaning Intervention; Assigned to Arm(s): 1
C: Arm Label: Nutrition and Physical Activity; Type: EXPERIMENTAL; Interventions: Behavioral: The Food Friends | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Food Friends; Assigned to Arm(s): Nutrition and Physical Activity
D: Arm Label: Scouting curricular implementation; Type: EXPERIMENTAL; Interventions: Behavioral: Scouting Nutrition and Activity Program | Arm Label: Standard-care attentional control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard-care attentional control | Intervention Type: BEHAVIORAL; Name: Scouting Nutrition and Activity Program; Assigned to Arm(s): Scouting curricular implementation | Intervention Type: BEHAVIORAL; Name: Standard-care attentional control; Assigned to Arm(s): Standard-care attentional control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome
Brief Summary: The purpose of this study is to estimate the risk of bleeding with rivaroxaban, compared with acetylsalicylic acid (ASA), in addition to a single antiplatelet/ platelet adenosine diphosphate P2Y12 receptor antagonist (P2Y12 inhibitor agent: clopidogrel or ticagrelor), in participants with a recent acute coronary syndrome (ACS: including ST segment elevation myocardial infarction \[STEMI\] and non-ST-segment elevation acute coronary syndrome \[NSTE-ACS\]).


Options:
A: Arm Label: Stratum 1/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Clopidogrel | Arm Label: Stratum 1/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Clopidogrel | Arm Label: Stratum 2/ASA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid, Drug: Ticagrelor | Arm Label: Stratum 2/Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Drug: Ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid; Assigned to Arm(s): Stratum 1/ASA, Stratum 2/ASA | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Stratum 1/Rivaroxaban, Stratum 2/Rivaroxaban | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Stratum 1/ASA, Stratum 1/Rivaroxaban | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Stratum 2/ASA, Stratum 2/Rivaroxaban
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 90 mg | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor 60 mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ticagrelor Placebo | Intervention Type: DRUG; Name: Ticagrelor 90 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ticagrelor 60 mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ticagrelor Placebo; Assigned to Arm(s): 3
C: Arm Label: ischemic heart disease; Type: N/A; Interventions: N/A | Arm Label: non-ischemic heart disease; Type: N/A; Interventions: N/A
D: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Brief Summary: The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).


Options:
A: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
C: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Interferon beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Placebo to ozanimod | Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to ozanimod; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to interferon beta-1a; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg

Answer: D